ADMA Stock Analysis
AD
Uncovered
ADMA Biologics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 527 full-time employees. The company went IPO on 2013-10-17. The company develops, manufactures, and markets specialty plasma-based biologics for the treatment and prevention of infectious diseases. The company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its patients include immune-compromised individuals who suffer from an underlying immune deficiency disorder and immune-suppressed for medical reasons. Its product candidates include BIVIGAM, an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI); ASCENIV an IVIG product indicated for the treatment of PI, and Nabi-HB which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg). Its ADMA BioCenters subsidiary operates source plasma collection facilities in the United States. Its Plasma Collection Centers segment, provides a portion of its blood plasma for the manufacture of its products candidates.